<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">AD HOC NEWS</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.ad-hoc-news.de/boerse/news/ueberblick/gilead-sciences-aktie-isin-us3755581036-im-fokus/68649016">Die Gilead Sciences Aktie befindet sich nach jüngsten Nachrichten aus der Pharmabranche in einer Phase erhöhter Aufmerksamkeit, während der Gesamtmarkt zwischen Zinssorgen und KI-Euphorie schwankt. Für Anleger im deutschsprachigen Raum bleibt der Wert ein spezialisierter, aber chancenreicher Baustein im Gesundheitssektor, der sich unabhängig von DAX, ATX und SMI als Diversifikationsinstrument anbietet.</a>
    </div>

      <div class="me-0 me-md-5">
        Gilead Sciences Aktie (ISIN US3755581036) im Fokus
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negativ
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">MarketBeat</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketbeat.com/stock-ideas/these-3-cash-flow-machines-provide-stability-in-uncertain-markets/?utm_source=snapi">These 3 Cash Flow Machines Provide Stability in Uncertain Markets</a>
    </div>

      <div class="me-0 me-md-5">
        When times get tough for companies, cash flow is an essential element that can determine viability through a challenging market. Simply put, if a firm does not have the ability to meet its near-term obligations with its cash on hand, it risks collapsing.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/south-africa-seeks-local-production-gileads-hiv-prevention-drug-2026-03-05/">South Africa seeks local production of Gilead&#39;s HIV prevention drug</a>
    </div>

      <div class="me-0 me-md-5">
        South Africa is asking ​local drugmakers to start a process to make Gilead Sciences&#39; long-acting HIV prevention drug, lenacapavir, domestically, ‌in a push to bring production to the region where it is most needed.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4877744-gilead-sciences-inc-gild-presents-at-td-cowen-46th-annual-health-care-conference-transcript">Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260302007593/en/Gilead-Foundation-Awards-12-Million-to-Empower-Community-Health-Workers-and-Expand-HIV-Prevention-Initiatives-Across-14-States-and-the-District-of-Columbia/">Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia</a>
    </div>

      <div class="me-0 me-md-5">
        FOSTER CITY, Calif.--(BUSINESS WIRE)--GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4875818-10-best-cefs-this-month-average-yield-9-percent-february-2026">10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)</a>
    </div>

      <div class="me-0 me-md-5">
        The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/gileads-experimental-hiv-treatment-shows-low-discontinuation-rates-studies-2026-02-25/">Gilead&#39;s experimental HIV treatment shows low discontinuation rates in studies</a>
    </div>

      <div class="me-0 me-md-5">
        Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low discontinuation rates, positioning the single-tablet regimen as a potential option for patients to switch to after the virus is already suppressed.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Gilead-Sciences-US3755581036">Gilead Sciences</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260224254904/en/Gilead%E2%80%99s-Single-Tablet-Regimen-of-Bictegravir-and-Lenacapavir-Maintained-Virological-Suppression-in-People-With-HIV-Who-Switched-Antiretroviral-Therapy/">Gilead&#39;s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy</a>
    </div>

      <div class="me-0 me-md-5">
        FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
</div>
</template></turbo-stream>